SUNPHARMA - Sun Pharmaceutical Industries Limited
NSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Mumbai,
India
Type: Equity
SUNPHARMA price evolution
SUNPHARMA
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53610.8 | $50333.5 | ||
| Short term investments | $84739.3 | $76339.4 | ||
| Net receivables | $123856.7 | $107628.6 | ||
| Inventory | $98747.8 | $89968.1 | ||
| Total current assets | $390028.8 | $350149.8 | ||
| Long term investments | $47830.2 | $52146.5 | ||
| Property, plant & equipment | $113370.3 | $111688.9 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $744554.9 | $697998.7 | ||
| Current liabilities | ||||
| Accounts payable | $51087.6 | $44793.4 | ||
| Deferred revenue | ||||
| Short long term debt | $38069.1 | $7007.7 | ||
| Total current liabilities | $167014.9 | $172005.5 | ||
| Long term debt | $2299.2 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $180913.8 | $187337.6 | ||
| Shareholders' equity | ||||
| Retained earnings | $412363 | |||
| Other shareholder equity | $528780 | $477712.9 | ||
| Total shareholder equity | $531179.3 | $480112.2 | $480112.2 | $495362.5 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $50333.5 | $64455.1 | $56766.1 | $70623 |
| Short term investments | $76339.4 | $40059.9 | $30740.1 | $27214.2 |
| Net receivables | $107628.6 | $91174.1 | $105105.8 | $100629.9 |
| Inventory | $89968.1 | $89970.2 | $78749.9 | $78859.8 |
| Total current assets | $350149.8 | $304420.8 | $316541.6 | $310691.9 |
| Long term investments | $52146.5 | $65781.7 | $52457.5 | $39518.1 |
| Property, plant & equipment | $111688.9 | $111715.1 | $112263.4 | $109382.1 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $697998.7 | $676667.3 | $682524.6 | $646938.1 |
| Current liabilities | ||||
| Accounts payable | $44793.4 | $39736.6 | $40937.3 | $41478.7 |
| Deferred revenue | ||||
| Short long term debt | $2322.5 | $4238.8 | $6438.6 | $5860.9 |
| Total current liabilities | $172005.5 | $161456.3 | $157064.3 | $173396.2 |
| Long term debt | $2299.2 | $8981.3 | $17776.1 | $14228.7 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $187337.6 | $181869 | $191277.7 | $199712.1 |
| Shareholders' equity | ||||
| Retained earnings | $412363 | $401887.4 | $389052 | $369130.4 |
| Other shareholder equity | $477712.9 | $462228.5 | $49319.1 | $30628 |
| Total shareholder equity | $480112.2 | $464627.8 | $452644.5 | $414090.6 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $109522.8 | $107617.6 | $94467.6 | $98630.6 |
| Cost of revenue | $27080.7 | $29002 | $25396.3 | $26406.2 |
| Gross Profit | $82442.1 | $78615.6 | $69071.3 | $72224.4 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $20045.6 | $20748.5 | $18849.1 | $18509.1 |
| Total operating expenses | $83642.1 | $86110.4 | $78238.8 | $77998.2 |
| Operating income | $25880.7 | $21507.2 | $16228.8 | $20632.4 |
| Income from continuing operations | ||||
| EBIT | $25880.7 | $21507.2 | $16228.8 | $20632.4 |
| Income tax expense | $1522.6 | $1889.9 | $1467.6 | $3353.9 |
| Interest expense | -$193.9 | -$136.9 | -$373.4 | -$189.7 |
| Net income | ||||
| Net income | $22622.2 | $20608.8 | -$22772.5 | $20588 |
| Income (for common shares) | $22622.2 | $20608.8 | -$22772.5 | $20588 |
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $386544.9 | $334981.4 | $328375 | $290659.1 |
| Cost of revenue | $103515.4 | $86900.8 | $96796.3 | $83838.9 |
| Gross Profit | $283029.5 | $248080.6 | $231578.7 | $206820.2 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $73008.3 | $68622.3 | $63985.9 | $60998.5 |
| Total operating expenses | $305544.7 | $271103.7 | $278657.3 | $243286 |
| Operating income | $81000.2 | $63877.7 | $49717.7 | $47373.1 |
| Income from continuing operations | ||||
| EBIT | $81000.2 | $63877.7 | $49717.7 | $47373.1 |
| Income tax expense | $10755 | $9242 | $8228 | $6008.8 |
| Interest expense | -$1273.5 | -$1414.3 | -$3027.3 | -$5505.8 |
| Net income | ||||
| Net income | $32727.3 | $29038.2 | $37649.3 | $26654.2 |
| Income (for common shares) | $32727.3 | $29038.2 | $37649.3 | $26654.2 |
| (in millions $) | 29 Sep 2022 | 29 Jun 2022 | 30 Mar 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | $22622.2 | $20608.8 | -$22772.5 | $20588 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | ||||
| (in millions $) | 30 Mar 2022 | 30 Mar 2021 | 30 Mar 2020 | 30 Mar 2019 |
|---|---|---|---|---|
| Net income | $32727.3 | $29038.2 | $37649.3 | $26654.2 |
| Operating activities | ||||
| Depreciation | $21437.4 | $20799.5 | $20084.8 | $17229.3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $89845.4 | $61703.7 | $65547.7 | $21964.5 |
| Investing activities | ||||
| Capital expenditures | -$14950.4 | -$11701.3 | -$15420 | -$32128.2 |
| Investments | -$37910.7 | $13732.7 | -$17019.2 | $17524.4 |
| Total cash flows from investing | -$57247.4 | $5362.2 | -$25888.4 | -$6812.5 |
| Financing activities | ||||
| Dividends paid | -$21589.2 | -$15594.7 | -$13791.9 | -$4801.8 |
| Sale and purchase of stock | ||||
| Net borrowings | -$27653.6 | -$44896.4 | -$31229.9 | -$2372 |
| Total cash flows from financing | -$51934.6 | -$59804.8 | -$57151.4 | -$27305.2 |
| Effect of exchange rate | $1274.3 | -$1296.9 | $3635.2 | $3256.5 |
| Change in cash and equivalents | -$17647.8 | $5964.2 | -$13856.9 | -$8441.5 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $410.24B |
|---|---|
| EBITDA | N/A |
| EBIT | $84.25B |
| Net Income | $41.05B |
| Revenue Q/Q | 13.78% |
| Revenue Y/Y | 11.77% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | 8.26% |
| Debt/Equity | 0.39 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.34 |
| Quick ratio | 1.74 |